156 related articles for article (PubMed ID: 27378518)
21. Haematologists usually over-estimate the percentage of CD138+ plasma cells in marrow biopsies.
Chai KY; Boyke Berahmana AA; Morison IM
Pathology; 2019 Oct; 51(6):647-648. PubMed ID: 31470997
[No Abstract] [Full Text] [Related]
22. Development of an unbiased, semi-automated approach for classifying plasma cell immunophenotype following multicolor flow cytometry of bone marrow aspirates.
Post SR; Post GR; Nikolic D; Owens R; Insuasti-Beltran G
Cytometry B Clin Cytom; 2018 Sep; 94(5):602-610. PubMed ID: 29573142
[TBL] [Abstract][Full Text] [Related]
23. Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders.
Foulk B; Schaffer M; Gross S; Rao C; Smirnov D; Connelly MC; Chaturvedi S; Reddy M; Brittingham G; Mata M; Repollet M; Rojas C; Auclair D; DeRome M; ; Weiss B; Sasser AK
Br J Haematol; 2018 Jan; 180(1):71-81. PubMed ID: 29105742
[TBL] [Abstract][Full Text] [Related]
24. Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: correlation with CD38/CD138 expressing myeloma cells.
Ak I; Aslan V; Vardareli E; Gülbaş Z
Ann Hematol; 2003 Feb; 82(2):88-92. PubMed ID: 12601486
[TBL] [Abstract][Full Text] [Related]
25. The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells.
Ng AP; Wei A; Bhurani D; Chapple P; Feleppa F; Juneja S
Haematologica; 2006 Jul; 91(7):972-5. PubMed ID: 16818287
[TBL] [Abstract][Full Text] [Related]
26. Automated digital enumeration of plasma cells in bone marrow trephine biopsies of multiple myeloma.
Malherbe JAJ; Fuller KA; Mirzai B; Augustson BM; Erber WN
J Clin Pathol; 2022 Jan; 75(1):50-57. PubMed ID: 33234694
[TBL] [Abstract][Full Text] [Related]
27. A GEIL flow cytometry consensus proposal for quantification of plasma cells: application to differential diagnosis between MGUS and myeloma.
Frébet E; Abraham J; Geneviève F; Lepelley P; Daliphard S; Bardet V; Amsellem S; Guy J; Mullier F; Durrieu F; Venon MD; Leleu X; Jaccard A; Faucher JL; Béné MC; Feuillard J;
Cytometry B Clin Cytom; 2011 May; 80(3):176-85. PubMed ID: 21520405
[TBL] [Abstract][Full Text] [Related]
28. Neoplastic plasma cell aberrant antigen expression patterns and their association with genetic abnormalities.
Salama ME; Du S; Efimova O; Heikal NM; Wendlandt E; Toydemir RM; South S; Perkins SL; Hussong JW; Zhan F
Leuk Lymphoma; 2015 Feb; 56(2):426-33. PubMed ID: 24913506
[TBL] [Abstract][Full Text] [Related]
29. Seemingly insignificant, but crucial morphological leads in the diagnosis of non-secretory multiple myeloma in an adolescent.
Mishra J; Chopra A; Gogia A; Kumar R
Indian J Pathol Microbiol; 2012; 55(1):130-2. PubMed ID: 22499328
[No Abstract] [Full Text] [Related]
30. Plasmablastic IgM multiple myeloma with hypocellular bone marrow.
Arter ZL; Miles D; Mignano S; Cordaro D; Roswarski J
Ann Hematol; 2020 Apr; 99(4):895-896. PubMed ID: 32055929
[No Abstract] [Full Text] [Related]
31. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.
Gonsalves WI; Timm MM; Rajkumar SV; Morice WG; Dispenzieri A; Buadi FK; Lacy MQ; Dingli D; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK
Leuk Res; 2016 May; 44():32-9. PubMed ID: 26994849
[TBL] [Abstract][Full Text] [Related]
32. CD71 (transferrin receptor): an effective marker for erythroid precursors in bone marrow biopsy specimens.
Marsee DK; Pinkus GS; Yu H
Am J Clin Pathol; 2010 Sep; 134(3):429-35. PubMed ID: 20716799
[TBL] [Abstract][Full Text] [Related]
33. An analysis of the false negative rate of minimal residual disease measurement by multiparameter flow cytometry in multiple myeloma.
Austin M; O'Connor S; Morilla R; Pawlyn C; Kaiser MF; Boyd KD
Int J Lab Hematol; 2020 Apr; 42(2):e65-e67. PubMed ID: 31539199
[No Abstract] [Full Text] [Related]
34. [Optimizing plasma cell content in bone marrow aspirates].
Hoffmann T; Favre G; Gratwohl A; Passweg J; Mathys S; Borel J; Speck B; Tichelli A
Schweiz Med Wochenschr; 1998 Oct; 128(42):1611-3. PubMed ID: 9824893
[TBL] [Abstract][Full Text] [Related]
35. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.
Pojero F; Flores-Montero J; Sanoja L; Pérez JJ; Puig N; Paiva B; Bottcher S; van Dongen JJ; Orfao A;
Cytometry B Clin Cytom; 2016 Jan; 90(1):91-100. PubMed ID: 26130131
[TBL] [Abstract][Full Text] [Related]
36. Plasma Cell Myeloma Mimicking Metastatic Carcinoma with CD138 positivity: a Potential Diagnostic Pitfall.
Wang H; Zhang J; He C; Peng F; Liu Z; Xiao D
Clin Lab; 2022 Mar; 68(3):. PubMed ID: 35254033
[TBL] [Abstract][Full Text] [Related]
37. [The value of multiparameter flow cytometry in diagnosis of lymphocytic leukemia and bone marrow involvement of non-Hodgkin's lymphoma].
Sun XF; He LR; Feng HL; Yan SL; Xia ZJ; Chen XQ
Ai Zheng; 2003 Nov; 22(11):1232-6. PubMed ID: 14613660
[TBL] [Abstract][Full Text] [Related]
38. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.
Liu D; Lin P; Hu Y; Zhou Y; Tang G; Powers L; Medeiros LJ; Jorgensen JL; Wang SA
J Clin Pathol; 2012 Sep; 65(9):823-9. PubMed ID: 22685235
[TBL] [Abstract][Full Text] [Related]
39. Intravoxel incoherent motion imaging for assessment of bone marrow infiltration of monoclonal plasma cell diseases.
Shah R; Stieltjes B; Andrulis M; Pfeiffer R; Sumkauskaite M; Delorme S; Schlemmer HP; Goldschmidt H; Landgren O; Hillengass J
Ann Hematol; 2013 Nov; 92(11):1553-7. PubMed ID: 23680869
[TBL] [Abstract][Full Text] [Related]
40. [Plasma cell separation algorithm from bone marrow samples].
Buresová I; Kyjovská D; Kovárová L; Moravcová J; Suská R; Perutka T; Cumová J; Hájek R
Klin Onkol; 2011; 24(1):35-40. PubMed ID: 21542274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
